Double-blind, randomized, placebo-controlled, parallel-group, two-arm, multi-center phase II trial to assess the safety, tolerability, and efficacy of DP-VPA (up to 900 mg) once daily for 10 weeks in adult subjects with migraine

Trial Profile

Double-blind, randomized, placebo-controlled, parallel-group, two-arm, multi-center phase II trial to assess the safety, tolerability, and efficacy of DP-VPA (up to 900 mg) once daily for 10 weeks in adult subjects with migraine

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 May 2009

At a glance

  • Drugs DP-VPA (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors D-Pharm
  • Most Recent Events

    • 06 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top